Table 1 Patient and tumor characteristics
From: Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
Characteristic | Stiftung Tumorbank Basel data set | The Netherlands Cancer Institute data set |
|---|---|---|
Method | Quantitative RT-PCR | Agilent Microarray |
n | 317 | 295 |
Age | ||
Mean/median (years) | 60/59 | 44/44 |
≤ 40 years | 20 (6%) | 75 (25%) |
41–55 years | 110 (35%) | 220 (75%) |
≥ 56 years | 187 (59%) | 0 (0%) |
pT stage | ||
pT1 | 100 (32%) | 155 (53%) |
pT2 | 183 (58%) | 140 (47%) |
pT3/4 | 33 (10%) | 0 |
pN status | ||
Negative | 161 (54%) | 151 (51%) |
Positive | 136 (46%) | 144 (49%) |
Unknown | 20 | 0 |
Histological grade | ||
1 (good) | 28 (9%) | 75 (25%) |
2 (intermediate) | 137 (46%) | 101 (34%) |
3 (poor) | 133 (45%) | 119 (41%) |
Unknown | 19 | 0 |
Estrogen receptor statusa | ||
Positive | 231 (73%) | 226 (77%) |
Negative | 86 (27%) | 69 (23%) |
ErbB2 status | ||
Positive | 70 (22%) | 52 (18%) |
Negative | 247 (78%) | 243 (82%) |
Adjuvant therapy | ||
None | 60 (20%) | 165 (56%) |
Hormone | 135 (44%) | 20 (7%) |
Chemotherapy | 72 (24%) | 90 (30%) |
Combination | 38 (12%) | 20 (7%) |
Total | 245 (80%) | 130 (44%) |
Unknown | 12 | 0 |
Follow-up | ||
Events (metastases) | 57 (18%) | 101 (34%) |
Mean/median metastasis-free survival (years) | 3.7/3.6 | 7.3/6.8 |